MA52286A - Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine - Google Patents
Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamineInfo
- Publication number
- MA52286A MA52286A MA052286A MA52286A MA52286A MA 52286 A MA52286 A MA 52286A MA 052286 A MA052286 A MA 052286A MA 52286 A MA52286 A MA 52286A MA 52286 A MA52286 A MA 52286A
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydroisoquinolein
- pyrazo
- dopamine
- receptor
- derivatives
- Prior art date
Links
- 102000004076 Dopamine D1 Receptors Human genes 0.000 title 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660622P | 2018-04-20 | 2018-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52286A true MA52286A (fr) | 2021-05-12 |
Family
ID=66324031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052286A MA52286A (fr) | 2018-04-20 | 2019-04-17 | Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10611751B2 (fr) |
| EP (1) | EP3781560B1 (fr) |
| JP (1) | JP7083916B2 (fr) |
| KR (1) | KR102520872B1 (fr) |
| CN (1) | CN111971282B (fr) |
| AR (1) | AR114467A1 (fr) |
| AU (1) | AU2019256350B2 (fr) |
| BR (1) | BR112020019934A2 (fr) |
| CA (1) | CA3097692C (fr) |
| CL (1) | CL2020002697A1 (fr) |
| CO (1) | CO2020012678A2 (fr) |
| CR (1) | CR20200481A (fr) |
| EA (1) | EA202092146A1 (fr) |
| EC (1) | ECSP20066271A (fr) |
| ES (1) | ES2927142T3 (fr) |
| IL (1) | IL278045B2 (fr) |
| JO (1) | JOP20200263A1 (fr) |
| MA (1) | MA52286A (fr) |
| MX (1) | MX2020010914A (fr) |
| MY (1) | MY197645A (fr) |
| NZ (1) | NZ767900A (fr) |
| PE (1) | PE20201151A1 (fr) |
| PH (1) | PH12020551713A1 (fr) |
| SA (1) | SA520420382B1 (fr) |
| SG (1) | SG11202009938TA (fr) |
| TW (1) | TWI725408B (fr) |
| UA (1) | UA125271C2 (fr) |
| WO (1) | WO2019204418A1 (fr) |
| ZA (1) | ZA202006439B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3993794A1 (fr) | 2019-07-01 | 2022-05-11 | UCB Biopharma SRL | Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1 |
| CA3139622A1 (fr) | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | Derive de tetrahydroisoquinoleine substitue utilise comme modulateur allosterique positif de d1 |
| US20240083875A1 (en) | 2020-12-18 | 2024-03-14 | UCB Biopharma SRL | Dihydroisoquinolinyl derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68910999T2 (de) | 1988-02-19 | 1994-03-24 | Smithkline Beecham Farma | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten. |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| WO2001085695A1 (fr) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| AR095883A1 (es) | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| CA2963951C (fr) * | 2014-10-08 | 2023-02-28 | Ucb Biopharma Sprl | Derives de tetrahydroisoquinoline |
| EP3204374B1 (fr) | 2014-10-08 | 2019-04-03 | UCB Biopharma SPRL | Dérivés d'isoindoline |
| AR105025A1 (es) | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | Compuesto de imidazodiazepina |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| EP3442945B1 (fr) | 2016-04-13 | 2020-07-08 | UCB Biopharma SRL | Derives de tetrhydroisoquinolines |
| EP3418270A1 (fr) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Nouveaux biphénylsulfoximines comme modulateurs allostériques du récepteur de la dopamine d1 |
| WO2019173437A1 (fr) | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulateurs allostériques positifs du récepteur de la dopamine 1 et procédé d'utilisation associé |
-
2019
- 2019-04-03 TW TW108111844A patent/TWI725408B/zh active
- 2019-04-04 AR ARP190100882A patent/AR114467A1/es unknown
- 2019-04-17 JP JP2020557950A patent/JP7083916B2/ja active Active
- 2019-04-17 SG SG11202009938TA patent/SG11202009938TA/en unknown
- 2019-04-17 KR KR1020207029608A patent/KR102520872B1/ko active IP Right Grant
- 2019-04-17 UA UAA202005900A patent/UA125271C2/uk unknown
- 2019-04-17 IL IL278045A patent/IL278045B2/en unknown
- 2019-04-17 BR BR112020019934-6A patent/BR112020019934A2/pt unknown
- 2019-04-17 CN CN201980027079.8A patent/CN111971282B/zh active Active
- 2019-04-17 US US16/386,684 patent/US10611751B2/en active Active
- 2019-04-17 PE PE2020001478A patent/PE20201151A1/es unknown
- 2019-04-17 ES ES19720352T patent/ES2927142T3/es active Active
- 2019-04-17 JO JOP/2020/0263A patent/JOP20200263A1/ar unknown
- 2019-04-17 CA CA3097692A patent/CA3097692C/fr active Active
- 2019-04-17 MY MYPI2020005419A patent/MY197645A/en unknown
- 2019-04-17 MA MA052286A patent/MA52286A/fr unknown
- 2019-04-17 CR CR20200481A patent/CR20200481A/es unknown
- 2019-04-17 WO PCT/US2019/027842 patent/WO2019204418A1/fr active Application Filing
- 2019-04-17 NZ NZ767900A patent/NZ767900A/en unknown
- 2019-04-17 MX MX2020010914A patent/MX2020010914A/es unknown
- 2019-04-17 EP EP19720352.4A patent/EP3781560B1/fr active Active
- 2019-04-17 AU AU2019256350A patent/AU2019256350B2/en active Active
- 2019-04-17 EA EA202092146A patent/EA202092146A1/ru unknown
-
2020
- 2020-10-09 PH PH12020551713A patent/PH12020551713A1/en unknown
- 2020-10-13 CO CONC2020/0012678A patent/CO2020012678A2/es unknown
- 2020-10-16 ZA ZA2020/06439A patent/ZA202006439B/en unknown
- 2020-10-16 CL CL2020002697A patent/CL2020002697A1/es unknown
- 2020-10-19 SA SA520420382A patent/SA520420382B1/ar unknown
- 2020-10-19 EC ECSENADI202066271A patent/ECSP20066271A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43512A (fr) | Composés hétérocycliques utiles en tant que modulateurs du tnf alpha | |
| MA49128A (fr) | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA54169A (fr) | Tolyles substitués utilisés en tant que fongicides | |
| MA49126A (fr) | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA43864A (fr) | Utilisation de dérivés de thiohydantoin substitué en tant qu'antagonistes des récepteurs d'androgènes | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA44502A (fr) | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| DK3433234T3 (da) | Allosteriske modulatorer af nicotinacetylcholinreceptorer | |
| MA48943A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA43251A (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| DK3630724T3 (da) | Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus | |
| MA41341A (fr) | Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA47370A (fr) | Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines | |
| MA42810A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA46665A (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA52286A (fr) | Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine | |
| DK3022174T3 (da) | Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer | |
| MA51133A (fr) | Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc | |
| MA44772A (fr) | 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t | |
| CL2020000139A1 (es) | Moduladores de lxr que contienen amina o (tio)amida. | |
| MA46859A (fr) | Dérivés d'indole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2 |